MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Incyte Corp

Închisă

SectorSănătate

68.47 0.15

Rezumat

Modificarea prețului

24h

Curent

Minim

68.31

Maxim

68.93

Indicatori cheie

By Trading Economics

Venit

-43M

158M

Vânzări

-126M

1.1B

P/E

Medie Sector

340.5

40.527

EPS

1.16

Marjă de profit

15.025

Angajați

2,617

EBITDA

-80M

257M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+11.95% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.9B

13B

Deschiderea anterioară

68.32

Închiderea anterioară

68.47

Sentimentul știrilor

By Acuity

72%

28%

341 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iul. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 iul. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 iul. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 iul. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 iul. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 iul. 2025, 15:49 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 iul. 2025, 15:49 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 iul. 2025, 15:49 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Received All Required Authorizations

4 iul. 2025, 15:48 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 iul. 2025, 15:47 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: Agreement Was Announced on Dec. 19

4 iul. 2025, 15:47 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 iul. 2025, 15:46 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 iul. 2025, 14:30 UTC

Achiziții, Fuziuni, Preluări

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 iul. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 iul. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 iul. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 iul. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 iul. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 iul. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 iul. 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 iul. 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 iul. 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 iul. 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

11.95% sus

Prognoză pe 12 luni

Medie 76.63 USD  11.95%

Maxim 107 USD

Minim 52 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

7

Cumpărare

9

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

341 / 375 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation